Y Intercept Hong Kong Ltd Takes $510,000 Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Y Intercept Hong Kong Ltd purchased a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,147 shares of the medical device company’s stock, valued at approximately $510,000.

Other hedge funds have also made changes to their positions in the company. Brooklyn Investment Group acquired a new stake in shares of Tandem Diabetes Care during the third quarter valued at $28,000. Assetmark Inc. purchased a new position in shares of Tandem Diabetes Care in the 3rd quarter worth about $29,000. McIlrath & Eck LLC purchased a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $52,000. Venturi Wealth Management LLC raised its holdings in shares of Tandem Diabetes Care by 5,955.9% during the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock valued at $74,000 after buying an additional 2,025 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $105,000.

Tandem Diabetes Care Stock Up 1.8 %

TNDM opened at $22.14 on Friday. Tandem Diabetes Care, Inc. has a one year low of $20.36 and a one year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The stock’s fifty day moving average is $34.95 and its 200-day moving average is $36.40. The company has a market capitalization of $1.45 billion, a PE ratio of -11.47 and a beta of 1.32.

Wall Street Analyst Weigh In

TNDM has been the topic of several analyst reports. Citigroup dropped their price objective on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Canaccord Genuity Group restated a “buy” rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday. Robert W. Baird dropped their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a report on Thursday. Barclays decreased their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Sanford C. Bernstein lowered Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $35.00 to $25.00 in a research report on Friday. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.88.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.